extract: 2026-03-21-semaglutide-us-import-wall-gray-market-pressure

Pentagon-Agent: Epimetheus <3D35839A-7722-4740-B93D-51157F7D5E70>

domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -138,6 +138,12 @@ India's March 20 2026 patent expiration launched 50+ generic brands at 50-60% pr
 
 Natco Pharma launched generic semaglutide in India at ₹1,290/month ($15.50) on March 20, 2026, the day the patent expired. This is 90% below innovator pricing and 2-3x lower than analyst projections made days earlier ($40-77/month within a year). 50+ manufacturers from 40+ companies are entering the market, with Sun Pharma, Zydus, Dr. Reddy's, and Eris launching on Day 1. The 'inflationary through 2035' timeline is empirically wrong for international markets—price compression is happening in 2026, not 2030+.
 
+### Additional Evidence (extend)
+*Source: [[2026-03-21-semaglutide-us-import-wall-gray-market-pressure]] | Added: 2026-03-21*
+
+US patent protection extends to 2031-2033 for Ozempic and Wegovy, creating a legal wall that prevents approved generic competition until then. The compounding pharmacy channel that provided affordable access during 2023-2025 closed in February 2025 when FDA removed semaglutide from the shortage list. This means the US will remain 'inflationary' through legal channels through 2031-2033, but gray market pressure from $15/month Indian generics versus $1,200/month Wegovy will create illegal importation at scale.
+
+
 
 Relevant Notes:
 - [[the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline]] -- GLP-1s are the largest single contributor to the inflationary cost trajectory

inbox/queue/.extraction-debug/2026-03-21-semaglutide-us-import-wall-gray-market-pressure.json

@@ -0,0 +1,32 @@
+{
+  "rejected_claims": [
+    {
+      "filename": "fda-compounding-pharmacy-closure-february-2025-eliminated-quasi-legal-affordable-glp1-access.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    },
+    {
+      "filename": "gray-market-semaglutide-importation-will-build-despite-illegality-due-to-1185-monthly-arbitrage.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    }
+  ],
+  "validation_stats": {
+    "total": 2,
+    "kept": 0,
+    "fixed": 2,
+    "rejected": 2,
+    "fixes_applied": [
+      "fda-compounding-pharmacy-closure-february-2025-eliminated-quasi-legal-affordable-glp1-access.md:set_created:2026-03-21",
+      "gray-market-semaglutide-importation-will-build-despite-illegality-due-to-1185-monthly-arbitrage.md:set_created:2026-03-21"
+    ],
+    "rejections": [
+      "fda-compounding-pharmacy-closure-february-2025-eliminated-quasi-legal-affordable-glp1-access.md:missing_attribution_extractor",
+      "gray-market-semaglutide-importation-will-build-despite-illegality-due-to-1185-monthly-arbitrage.md:missing_attribution_extractor"
+    ]
+  },
+  "model": "anthropic/claude-sonnet-4.5",
+  "date": "2026-03-21"
+}

inbox/queue/2026-03-21-semaglutide-us-import-wall-gray-market-pressure.md

@@ -7,9 +7,13 @@ date: 2026-03-21
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: enrichment
 priority: medium
 tags: [glp1, semaglutide, us-importation, compounding-pharmacy, fda, gray-market, patent-wall, personal-import]
+processed_by: vida
+processed_date: 2026-03-21
+enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -74,3 +78,14 @@ PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic catego
 WHY ARCHIVED: This documents the mechanism that keeps the US "inflationary" claim partially true for legal channels while explaining why the claim is being eroded by gray market channels. The compounding closure and import wall are the specific regulatory barriers that maintain the US/international price gap.
 
 EXTRACTION HINT: The extractor should focus on: (1) February 2025 compounding closure — the specific date the legal access pathway closed; (2) FDA's explicit gray market warning — this is an admission that price arbitrage will produce illegal importation at scale; (3) the 2031-2033 patent expiry as the only legal resolution date for the US market.
+
+
+## Key Facts
+- FDA removed injectable semaglutide from drug shortage list on February 21, 2025
+- India semaglutide patents expired March 2026
+- Novo Nordisk's higher-dose Wegovy received FDA approval March 20, 2026
+- FDA established import alert 66-80 to screen non-compliant GLP-1 APIs
+- Natco generic semaglutide costs approximately $15/month
+- Wegovy costs approximately $1,200/month in the US
+- US patent protection for Ozempic extends to 2031-2033
+- Compounding pharmacies legally produced semaglutide during 2023-2025 shortage period